Diaceutics x Doceree Partnership: Power Precision HCP Targeting with Real-Time Diagnostic and Genomic Data
We are pleased to announce our partnership with Doceree. This collaboration creates a new industry standard for HCP targeting. It will help life sciences marketers reach treaters with unmatched clinical precision, at the exact moments that matter most. From this date, our AI-driven diagnostic and genomic data is now integrated with Doceree's Marketplace. They are the world’s first global network of physician-only programmatic platforms.
Our multimodal audience segments are built using real-world diagnostic, lab, and genomic profile data. These audiences are now directly accessible to media buyers within the Doceree ecosystem.
What does this partnership mean for HCP targeting?
Pharmaceutical marketers can harness the ability to go beyond traditional claims-based targeting. This allows engagement with physicians based on real-time diagnostic behaviors, biomarker testing, and disease progression insights. For media buyers, it means more accurate HCP targeting, faster activation and deeper visibility into true treaters. This enables more relevant messaging at the point of treatment decision.
Doceree empowers life sciences brands to connect with physicians across over 150 EHR, eRx, and telehealth platforms. It delivers targeted messaging in endemic and clinical environments where HCPs make decisions.
Marketers using Doceree now have access to over 100 pre-built audience segments. These include:
- General medicine (such as diabetes, CKD, and cardiovascular disease)
- Biomarker-driven precision therapies in oncology
- Select rare diseases
This level of HCP targeting will empower marketers to:
- Target HCPs based on a patient’s clinical journey and influence behavior at the point of treatment decision
- Close the recency gap inherent in claims data using real-time diagnostic and lab-based triggers
- Uncover and message those treating HCPs missed in absent claims but captured in the patient journey
“For marketers trying to influence physician behavior in real-time, data depth and context are everything. This partnership unlocks a new level of campaign intelligence. It will empower brand and omnichannel teams to engage treaters earlier, faster, and more meaningfully based on what’s actually happening with patients in the moment. As opposed to what happened months ago."
– Scott Phillips, VP, Real World Data at Diaceutics
“At Doceree, we’re reimagining how and where healthcare brands communicate with physicians. Partnering with Diaceutics enhances our ability to deliver truly relevant, timely engagement by aligning campaign execution to the real-world diagnostic journey. It’s a step forward in our mission to make HCP engagement smarter and more impactful across every moment of care.”
– Julius Ramirez, SVP Partnerships at Doceree
About Diaceutics
Every patient should have access to receive the right test and therapy to impact their disease outcome positively. For more than two decades, we have specialized in delivering precision medicine and diagnostic solutions to the world’s top pharma and biotechs. Our goal is to bridge the gap between biomarker testing and targeted therapies. This empowers industry partners to succeed in the evolving field of personalized healthcare.
About Doceree
Doceree is leading the way in making HCP-patient conversations richer and more meaningful. Their patented responsive technology addresses both current and emerging challenges for healthcare and life sciences organizations in HCP-patient engagement. They specialize in digital and technological advancements. Doceree's patented technology enables HCP-patient conversations and interactions to be more meaningful, richer, and outcome-oriented.
About Diaceutics
We’ve been with pharma and biotech companies for over 20 years, helping them to make more informed diagnostic and therapeutic decisions based on real-world data. Our platforms and tools provide global insight from a network of laboratories across 50+ countries.
This unparalleled visibility into real-world testing helps support therapy programs across oncology, cardiology, neurology, autoimmune, rare diseases, and many more.
What is the Diaceutics and Doceree partnership?
Diaceutics' AI-driven diagnostic and genomic data is now integrated with the Doceree Marketplace, the world's first global network of physician-only programmatic platforms. The partnership sets a new industry standard for HCP targeting. It helps life sciences marketers reach treaters with clinical precision at the moments that matter most.
How does diagnostic data improve HCP targeting beyond claims data?
Marketers can engage physicians based on real-time diagnostic behaviors, biomarker testing and disease progression insights, not on what happened months ago. This closes the recency gap inherent in claims data. For media buyers, it means more accurate HCP targeting, faster activation and deeper visibility into true treaters.
What audience segments are available through Diaceutics and Doceree?
Marketers using Doceree can access over 100 pre-built audience segments. They cover general medicine (such as diabetes, CKD and cardiovascular disease), biomarker-driven precision therapies in oncology, and select rare diseases.
How are Diaceutics' multimodal audience segments built?
The segments are built from real-world diagnostic, lab and genomic profile data. They are directly accessible to media buyers within the Doceree ecosystem.
Where can marketers reach HCPs through Doceree?
Doceree connects life sciences brands with physicians across over 150 EHR, eRx and telehealth platforms. It delivers targeted messaging in endemic and clinical environments where HCPs make decisions. That means messaging reaches physicians at the point of treatment decision.
How can marketers find treating HCPs missed by claims data?
